SCB-2019

BIOLOGICAL2 trials

Sponsors

Clover Biopharmaceuticals AUS Pty

Conditions

COVID-19

Phase 1

SCB-2019 as COVID-19 Vaccine

CompletedNCT04405908

Clover Biopharmaceuticals AUS PtyCOVID-19

Start: 2020-06-19End: 2021-12-08Updated: 2022-02-18

Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.

CompletedNCT04932824

Clover Biopharmaceuticals AUS PtyCOVID-19

Start: 2021-01-19End: 2021-12-16Updated: 2022-02-11

Related Papers

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents

Human Vaccines & Immunotherapeutics2023-01-026 citations

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.

2022-01-2559 citations

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.

2021-04-19100 citations

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.

2021-01-29220 citations